RYTM
RHYTHM PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$91.89
+6.31%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 280.7M | 189.8M | 130.1M | 77.4M | 23.6M |
| Cost of Revenue | 33.1M | 19.5M | 13.4M | 9.3M | 2.1M |
| Gross Profit | 247.7M | 170.3M | 116.8M | 68.1M | 21.5M |
| Operating Expenses | |||||
| R&D Expense | 179.7M | 167.3M | 238.0M | 135.0M | 108.6M |
| SG&A Expense | 255.3M | 194.9M | 144.3M | 117.5M | 92.0M |
| General & Admin Expense | 66.8M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 434.9M | 362.3M | 382.3M | 252.5M | 200.7M |
| Cost and Expenses | 468.0M | 381.8M | 395.6M | 261.8M | 202.8M |
| Operating Income (EBIT) | (187.2M) | (192.0M) | (265.5M) | (184.4M) | (179.2M) |
| Non-Operating | |||||
| Interest Income | 14.0M | 15.3M | 14.7M | 13.9M | 4.0M |
| Interest Expense | 18.2M | 20.6M | 20.6M | 13.9M | 5.2M |
| Net Interest Income | (4.2M) | (5.3M) | (5.9M) | 53.0K | (1.2M) |
| Other Non-Op Income/Expense | (5.0M) | (4.0M) | 5.2M | 243.0K | (2.0M) |
| Non-Operating Income (excl Interest) | (13.2M) | (16.6M) | (25.9M) | (14.1M) | (3.2M) |
| EBT (Pre-Tax Income) | (192.2M) | (196.0M) | (260.3M) | (184.1M) | (181.1M) |
| Income Tax Expense | 1.6M | 497.0K | 346.0K | 564.0K | — |
| Bottom Line | |||||
| Net Income | (193.8M) | (196.5M) | (260.6M) | (184.7M) | (181.1M) |
| Earnings from Cont. Ops | (193.8M) | (196.5M) | (260.6M) | (184.7M) | (181.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (198.3M) | (201.9M) | (264.6M) | (184.7M) | (181.1M) |
| Per Share | |||||
| Basic EPS | ($2.90) | ($3.11) | ($4.34) | ($3.20) | ($3.51) |
| Diluted EPS | ($2.90) | ($3.11) | ($4.34) | ($3.20) | ($3.51) |
| Revenue Per Share | $4.07 | $2.92 | $2.13 | $1.34 | $0.45 |
| Shares | |||||
| Basic Shares Outstanding | 69.0M | 65.0M | 61.0M | 57.7M | 52.1M |
| Diluted Shares Outstanding | 69.0M | 65.0M | 61.0M | 57.7M | 52.1M |
| Profitability Metrics | |||||
| EBITDA | (173.2M) | (174.1M) | (238.1M) | (168.5M) | (174.2M) |
| D&A | 775.0K | 1.3M | 1.6M | 1.8M | 1.7M |
| EBIT | (174.0M) | (175.5M) | (239.7M) | (170.2M) | (175.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026